Difference between revisions of "Tacrolimus (Prograf)"
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as [[GVHD|graft versus host disease]], allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.<ref name="insert">[http://www.astellas.us/docs/prograf.pdf Tacrolimus (Prograf) package insert]</ref><ref>[ | + | Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as [[GVHD|graft versus host disease]], allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.<ref name="insert">[http://www.astellas.us/docs/prograf.pdf Tacrolimus (Prograf) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/tacrolimus.pdf Tacrolimus (Prograf) package insert (locally hosted backup)]</ref><ref>[http://prograf.com/ Prograf manufacturer's website]</ref> |
<br>Route: PO, IV | <br>Route: PO, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' FK-506 | *'''Code name:''' FK-506 | ||
| − | *'''Brand names:''' Advagraf, Prograf | + | *'''Brand names:''' Advagraf, Prograf, Tacforius |
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Calcineurin inhibitors]] | [[Category:Calcineurin inhibitors]] | ||
| − | |||
| − | [[Category: | + | |
| + | [[Category:FDA approved in 1994]] | ||
Latest revision as of 00:15, 6 July 2024
General information
Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as graft versus host disease, allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.[1][2][3]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Patient drug information
- Tacrolimus (Prograf) package insert PDF pages 38-42[1]
- Tacrolimus (Prograf) patient drug information (UpToDate)[4]
Also known as
- Code name: FK-506
- Brand names: Advagraf, Prograf, Tacforius